SEARCH

SEARCH BY CITATION

References

  • 1
    Falagas ME, Bliziotis IA. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29: 630636.
  • 2
    Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 13331341.
  • 3
    Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589601.
  • 4
    Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 125.
  • 5
    Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960967.
  • 6
    Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004; 10 (suppl 4): 19.
  • 7
    Petrosillo N, Chinello P, Proietti MF et al. Combined colistin and rifampin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005; 11: 682683.
  • 8
    Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 29462950.
  • 9
    Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41: 149158.
  • 10
    Bliziotis IA, Ntziora F, Lawrence KR, Falagas ME. Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 2007; 26: 849856.
  • 11
    Falagas ME, Matthaiou DK, Bliziotis IAJ. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639647.
  • 12
    Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328: 668.
  • 13
    Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326: 1111.
  • 14
    Hawley JS, Murray CK, Jorgensen JH. Development of colistin-dependent Acinetobacter baumannicalcoaceticus complex. Antimicrob Agents Chemother 2007; 51: 45294530.
  • 15
    Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 270271.
  • 16
    Hogg GM, Barra JG, Webb CH. In-vitro activity of the combination of colistin and rifampin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998; 41: 494495.
  • 17
    Rynn C, Wootton M, Bowker KE, Alan Holt, Reeves DS. In vitro assessment of colistin’s antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999; 5: 3236.
  • 18
    Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampicin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40: 117120.
  • 19
    Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2002; 44: 259263.
  • 20
    Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48: 753757.
  • 21
    Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003; 15: 235238.
  • 22
    Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotscahfer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905909.
  • 23
    Tascini C, Gemignani G, Ferranti S et al. Microbiological activity and clinical efficacy and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004; 16: 282287.
  • 24
    Hill D, Rose B, Pajkos A et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microb 2005; 43: 50855090.
  • 25
    Giacometti A, Cirioni O, Kamysz W et al. In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrob Agents Chemother 2005; 49: 12491252.
  • 26
    Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224228.
  • 27
    Cirioni O, Ghiselli R, Silvestri C et al. Efficacy of tachyplesin  III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 2007; 51: 20052010.
  • 28
    Song JY, Kee SY, Hwang IS et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60: 317322.
  • 29
    Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45: 594598.
  • 30
    Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 60: 421423.
  • 31
    Saslaw S, Carlisle HN, Moheimani M. Comparison of colistin–carbenicillin, colistin, and carbenicillin in Pseudomonas sepsis in monkeys. Antimicrob Agents Chemother 1973; 3: 118124.
  • 32
    Giacometti A, Cirioni O, Ghiselli R et al. Antiendotoxin activity of antimicrobial peptides and glycopeptides. J Chemother 2003; 15: 129133.
  • 33
    Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 10851091.
  • 34
    Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007; 29: 5155.
  • 35
    Cirioni O, Ghiselli R, Orlando F et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit Care Med 2007; 35: 17171723.
  • 36
    Tascini C, Gemignani G, Palumbo F et al. Clinical and microbiological effectiveness of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006; 18: 648651.
  • 37
    Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin–meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect 2006; 12: 12271230.
  • 38
    Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: 154160.
  • 39
    Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987993.
  • 40
    Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 31363146.
  • 41
    Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115121.
  • 42
    Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274278.
  • 43
    Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7: 7883.
  • 44
    Kallel H, Bahloul M, Hergafi L et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28: 366369.
  • 45
    Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 2002; 35: 901902.
  • 46
    Reina R, Estenssoro E, Saenz G et al. Safety and effectiveness of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31: 10581065.
  • 47
    Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 11111118.
  • 48
    Hachem RY, Chemaly RF, Ahmar CA et al. Colistin is effective in the treatment of multidrug-resistant Pseudomonas aeruginosa infections in cancer patients. Antimicrob Agents Chemother 2007; 51: 905911.
  • 49
    Pournaras S, Ikonomidis A, Markogiannakis A, Maniatis AN, Tsakris A. Heteroresistance to carbapenems in Acinetobacter baumannii. J Antimicrob Chemother 2005; 55: 10551056.
  • 50
    Rinder H. Hetero-resistance: an under-recognised confounder in diagnosis and therapy? J Med Microbiol 2001; 50: 10181020.